Biogen’s “post-MS” reset is hitting an inflection point—Alzheimer’s, rare disease, and SYFOVRE aim to replace legacy erosion, with the LEQEMBI subcutaneous decision as the pivotal near-term catalyst.
Overview
Biogen is transitioning from an MS-dominated biotech leader into a diversified neurology- and specialty-disease company, with the explicit goal of replacing declining legacy MS cash flows with newer, higher-growth assets. Revenue is generated through specialty drug sales, royalties (including meaningful anti-CD20 economics), and contract manufacturing, supported by a broad global footprint (about 50% of product revenue outside the U.S.). The portfolio is now effectively split between “Legacy Biogen” MS therapies (TYSABRI, TECFIDERA/VUMERITY, AVONEX/PLEGRIDY) and a “New Biogen” growth set: LEQEMBI (Alzheimer’s), SKYCLARYS (Friedreich’s Ataxia), ZURZUVAE (postpartum depression), and SPINRAZA (SMA, with life-cycle upgrades). The investment narrative centers on whether LEQEMBI and the rare disease assets can scale fast enough—and profitably enough—to overcome persistent MS erosion, while the company expands further via the Apellis/SYFOVRE transaction into geographic atrophy. Biogen’s differentiation is rooted in neurology heritage, deep real-world evidence, biologics manufacturing expertise, and the care-pathway infrastructure required for complex therapies (infusion capacity, monitoring protocols, specialist relationships). Near-term attention is concentrated on LEQEMBI’s subcutaneous PDUFA outcome and the operational integration of Apellis, which together are framed as pivotal to accelerating growth and driving a valuation re-rating.